Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nesp Biosame to Hit Japan Market in July-September 2019
The so-called “biosame” version of Kyowa Hakko Kirin’s flagship renal anemia drug Nesp (darbepoetin alfa) will be launched in the July-September quarter of 2019, Kyowa Hakko Kirin told analysts at an earnings briefing on October 30. Darbepoetin Alfa Injection Syringe…
To read the full story
Related Article
- Nesp Biosame to Hit Japan Shelves on August 5
July 29, 2019
- Chuikyo OKs 70% Pricing for Nesp Biosame; New Rules Up for FY2020 Reform Debate
March 28, 2019
- Nesp Biosame Likely to Be Priced at 70% of Originator as Stopgap Measure
March 26, 2019
- Authorized Generics for Iressa, Urief to Join NHI Price List; Nesp Biosame Skips Listing
December 13, 2018
- Balancing Act: All Eyes on Nesp Biosame Pricing before June 2019 Listing, Biosimilars to Follow in November
November 5, 2018
- 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
October 1, 2018
- Kyowa Kirin Mum on Listing Request Status for Nesp “Biosame”
August 24, 2018
- Nesp “Biosame” Could Hit Market as Early as December
August 17, 2018
- Japan Approves Nesp “Biosame,” Eyes Riveted on December Listing
August 16, 2018
BUSINESS
- Ultragenyx Seeks Japan Approval for GSDIa Gene Therapy
July 1, 2026
- Asahi Kasei Nabs Japan Rights to Additional Empaveli Indications
July 1, 2026
- Viatris Eyes Japan Filing This Year for IgAN Drug
July 1, 2026
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…